QNRX · Quoin Pharmaceuticals Ltd.
$4.45
-0.27 (-5.72%)
At close · Oct 2
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based upon the Company's current business plans and cash, cash equivalents, and investments on hand, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern for a period of at least one year from the date of the filing of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 14, 2026
Market Cap
$12.91M
Shares
2.01M
Volume · Oct 2
20.3K
Avg daily vol (3M)
541.6K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.72
Open$4.69
Day$4.50–4.80
52W close$3.25–22.30
Avg vol 30d1.1M
Short int126K · 6.3% float · 1.0d
Short vol58%
Last earningsMay 7, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 14
Up next
filed Aug 14, 2026
call held Mar 14, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$18.67M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$10.80M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+31.9%
Year over year · more shares
Price change (1Y)
-34.7%
Trailing year
Short interest
6.3%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−32%
below
Price vs 50-day avg
−17%
below
RSI (14)
33
neutral
MACD trend
Negative
52-week position
8%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−30%
trailing
6-month return
−20%
trailing
YTD return
−67%
this year
Relative strength
−32%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +1 funds added
Insider flow
Accumulating
Net +$280.0K over 90 days · 0% sells
Short interest
Falling
6.29% of float · ▼ -76.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
19 holders — mid 3-yr range
Squeeze score
39
low risk · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
197%
annualized · 1-yr
Max drawdown
−85%
past year
ATR
13.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−32%
Bearish
Price vs 50-day avg
−17%
Bearish
RSI (14)
33
Neutral
MACD trend
Negative
Bearish
52-week position
8%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $6 › 200d $7 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +1 funds added
Insider flow
Accumulating
Net +$280.0K over 90 days · 0% sells
Short interest
Falling
6.29% of float · ▼ -76.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
19 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $3
Now $5 · 8%
Range high $22
vs 200-day avg -32%
vs 50-day avg -17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QNRX
this stock
Quoin Pharmaceuticals Ltd.
|
$12.91M | -67.3% | — | — | 6.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.8% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +540.7% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QNRX | -26.0% | -30.0% | -20.0% | +3.5% | -67.3% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | -25.6% | -29.8% | -32.4% | +3.3% | -79.3% |